Search Result

Results for "

BAF3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (6) Apoptosis (12) Bacterial (2) Bcr-Abl (8) c-Fms (1) c-Kit (2) c-Met/HGFR (2) Cannabinoid Receptor (1) EGFR (14) FGFR (2) FLT3 (6) JAK (2) Ligands for E3 Ligase (4) PDGFR (2) PROTACs (1) Raf (1) Ras (1) RET (1) SARS-CoV (1) TAM Receptor (2) Thrombopoietin Receptor (2) Trk Receptor (9) VEGFR (1)
By Research Areas:	Cancer (57) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-121852

SCH 336 SCH-225336	Cannabinoid Receptor	Inflammation/Immunology
SCH 336 is a potent, selective, inverse and orally active CB2 agonist. SCH 336 inhibits BaF3/CB2 migration. SCH 336 significantly inhibits the migration of leukocytes in vivo. SCH 336 blocks ovalbumin-induced lung eosinophilia in mice .

HY-109020

Acrizanib

1 Publications Verification

LHA510
VEGFR Others

Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC₅₀ of 17.4 nM for BaF3-VEGFR-2 .
HY-18960

CHZ868

5 Publications Verification

JAK Cancer

CHZ868 is a type II JAK2 inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

Acrizanib 1 Publications Verification LHA510	VEGFR	Others
Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC₅₀ of 17.4 nM for BaF3-VEGFR-2 .

CHZ868 5 Publications Verification	JAK	Cancer
CHZ868 is a type II JAK2 inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

HY-156086

TRK-IN-24	Trk Receptor	Cancer
TRK-IN-24 (compound 10g) is a Trk Receptor inhibitor that inhibits TRKA, TRKC, TRKA ^G595R, TRKA ^G667C and TRKA ^F589L IC₅₀s are 5.21, 4.51, 6.77, 1.42 and 6.13 nM respectively. TRK-IN-24 has antitumor efficacy in BaF3-CD74-NTRK1 ^G595R and BaF3-CD74-NTRK1 ^G667C xenograft models. TRK-IN-24 inhibits the proliferation of Ba/F3 cells transfected with single mutants such as SF, GK, and xDFG, with an IC₅₀ of 1.43-47.56 nM .

HY-146210

EGFR-IN-50	EGFR	Cancer
EGFR-IN-50 (Compound 9h) is a potent EGFR inhibitor against L858R resistance mutation (TEL-EGFR-L858R-BaF3: GI₅₀=8 nM, TEL-EGFR-T790M-L858R-BaF3: GI₅₀=6.03 μM). EGFR-IN-50 shows anti-proliferative activity to cancer cells .

HY-163417

HER2-IN-15	EGFR	Cancer
HER2-IN-15 (Compound 1) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-15 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163418

HER2-IN-17	EGFR	Cancer
HER2-IN-17 (Compound 2) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-17 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163420

HER2-IN-16	EGFR	Cancer
HER2-IN-16 (Compound 14) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-16 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-104010

Asciminib 5 Publications Verification ABL001	Bcr-Abl	Cancer
Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC₅₀ of 0.25 nM .

HY-104010A

Asciminib hydrochloride 5 Publications Verification ABL001 hydrochloride	Bcr-Abl	Cancer
Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC₅₀ of 0.25 nM .

HY-142680

EGFR-IN-23

EGFR Cancer

EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC₅₀ of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8) .

EGFR-IN-23	EGFR	Cancer
EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC₅₀ of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8) .

HY-153724

BI-2865	Ras	Cancer
BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with K_Ds of 6.9, 4.5, 32, 26, 4.3 nM respectively. BI-2865 inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 cells (mean IC₅₀: roughly 140 nM) .

HY-18952A

(Z)-SU5614	FLT3 Apoptosis	Cancer
(Z)-SU5614 is a potent *FLT3* inhibitor and selectively induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3 .

HY-110026

GTP-14564	FLT3	Cancer
GTP-14564 is a tyrosine kinase inhibitor targeting to internal tandem duplication (ITD) and *FLT3*. GTP-14564 inhibits FLT3 ligand-dependent growth in Ba/F3 leukemia cells .

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies ^[3]. S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-155046

FGFR4-IN-14	FGFR	Cancer
FGFR4-IN-14 (Compound 27i) is a FGFR4 inhibitor (IC₅₀: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC₅₀s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .

HY-155227B

ALK/EGFR-IN-3	Anaplastic lymphoma kinase (ALK)	Cancer
ALK/EGFR-IN-3 is a dual inhibitor of ALK and EGFR. ALK/EGFR-IN-3 inhibits the cell proliferation of H1975, PC9, and Baf3-EML4-ALK cancer cell lines with IC₅₀s of 0.1360, 0.0332, and 0.0339 μM, respectively .

HY-156467

ALK-IN-27	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-27 (compound 1) is a potent ALK inhibitor. ALK-IN-27 shows antitumor activity. ALK-IN-27 has an IC₅₀ of 2.7 nM for Ba/F3 CLIP1-LTK cells .

HY-142517

EGFR-IN-25

EGFR Cancer

EGFR-IN-25 is a potent EGFR inhibitor with IC₅₀s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively .

EGFR-IN-25	EGFR	Cancer
EGFR-IN-25 is a potent EGFR inhibitor with IC₅₀s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively .

HY-147575

Axl-IN-8	TAM Receptor c-Met/HGFR	Cancer
Axl-IN-8 (NO.1) is a potent AXL inhibitor, with an IC₅₀ of <1 nM. Axl-IN-8 also inhibits c-MET, with an IC₅₀ of 1-10 nM. Axl-IN-8 shows anti-proliferative activity against BaF3/TEL-AXL, MKN45, and EBC-1 cells, with IC₅₀ values of <10, 226.6 and 120.3 nM, respectively .

HY-13491

GNF-5837 3 Publications Verification	Trk Receptor	Cancer
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC₅₀ values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .

HY-12291

HG6-64-1 HMSL 10017-101-1	Raf	Cancer
HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC₅₀ of 0.09 μM on B-raf V600E transformed Ba/F3 cells.

HY-142922

BCR-ABL-IN-4	Bcr-Abl	Cancer
BCR-ABL-IN-4 is a BCR-ABL inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC₅₀ values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11) .

HY-155227A

ALK/EGFR-IN-2	Anaplastic lymphoma kinase (ALK)	Cancer
ALK/EGFR-IN-2 is a potent dual inhibitor of ALK and EGFR. ALK/EGFR-IN-2 induces apoptosis and G0/G1 cell cycle arrest in cancer cells. ALK/EGFR-IN-2 significantly inhibits the cell proliferation of H1975, PC9, and Baf3-EML4-ALK cancer cell lines with IC₅₀s of 0.0034, 0.0065, and 0.0018 μM, respectively .

HY-156410

FLT3-IN-23	FLT3	Cancer
FLT3-IN-23 (compound 15) is an inhibitor of JFMS-like tyrosine kinase 3 (FLT3) with an IC₅₀ of 7.42 nM. FLT3-IN-23 has antiproliferative activities against BaF3 cells carrying various FLT3-TKD and FLT3-ITD-TKD mutations .

HY-156467A

ALK-IN-27 TFA	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-27 TFA is the TFA form of ALK-IN-27 (HY-156467). ALK-IN-27 (compound 1) is a potent ALK inhibitor. ALK-IN-27 shows antitumor activity. ALK-IN-27 has an IC₅₀ of 2.7 nM for Ba/F3 CLIP1-LTK cells .

HY-12083

PPY-A	Bcr-Abl	Cancer
PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC₅₀s of 9 and 20 nM, respectively. PPY-A inhibits Ba⁄F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC₅₀s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .

HY-155227

ALK/EGFR-IN-1	Anaplastic lymphoma kinase (ALK) EGFR Apoptosis	Cancer
ALK/EGFR-IN-1 (Compound 8l) is an ALK/EGFR dual inhibitor that blocks the phosphorylation of EGFR and ALK. ALK/EGFR-IN-1 inhibits ALK/EGFR mutants respectively, with IC₅₀ of 4.3 nM for EGFR L858R T790M in H1975 cells and EML4-ALK in BaF3 cells, respectively. and 3.6 nM. ALK/EGFR-IN-1 may be used in NSCLC research .

HY-162103

Axl-IN-18	TAM Receptor Apoptosis	Cancer
Axl-IN-18 (compound 25c) is a potent and selective type II AXL inhibitor. Axl-IN-18 shows excellent AXL inhibitory activity (IC₅₀=1.1 nM) and 343-fold selectivity over the highly homologous kinase MET in biochemical assays (IC₅₀=377 nM). Axl-IN-18 significantly inhibits AXL-driven cell proliferation, dose-dependently suppresses 4T1 cell migration and invasion, and induces apoptosis. Axl-IN-18 shows noticeable antitumor efficacy in a BaF3/TEL-AXL xenograft model .

HY-101763A

(S,R,S)-AHPC monohydrochloride 1 Publications Verification VH032-NH2 monohydrochloride; VHL ligand 1 monohydrochloride	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC (VH032-NH2) hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC hydrochloride can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC₅₀ of 1.11 μM in Ba/F3 cells .

HY-125845

(S,R,S)-AHPC 1 Publications Verification VH032-NH2; VHL ligand 1	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC₅₀ of 1.11 μM in Ba/F3 cells .

HY-101763B

(S,R,S)-AHPC dihydrochloride VH032-NH2 dihydrochloride; VHL ligand 1 dihydrochloride	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC (VH032-NH2) dihydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC dihydrochloride can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC₅₀ of 1.11 μM in Ba/F3 cells .

HY-110402

(S,R,S)-AHPC TFA VH032-NH2 TFA; VHL ligand 1 TFA	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC (VH032-NH2) TFA is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC TFA can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC₅₀ of 1.11 μM in Ba/F3 cells .

HY-133551

WF-47-JS03	RET	Cancer
WF-47-JS03 is a potent and selective RET kinase inhibitor with IC₅₀s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively. WF-47-JS03 demonstrates >500-fold selectivity against kinase insert domain receptor (KDR). Effective brain penetration .

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective JAK2 inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 ^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .

HY-155302

FLT3-IN-22	FLT3	Cancer
FLT3-IN-22 (compound 22f) is a potent *FLT3* inhibitor with IC₅₀ values of 0.941 nM and 0.199 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-22 exhibits strong antiproliferative activity against MV4-11 cells and the mutant FLT kinase expressed Ba/F3 cell lines, including FLT-D835Y and FLT3-F691L .

HY-155358

Os30	EGFR Apoptosis	Cancer
Os30, a potent fourth-generation EGFR inhibitor, is a potent EGFRC797S-TK inhibitor with IC₅₀ values of 18 nM and 113 nM for EGFRDel19/T790M/C797S TK and EGFRL858R/T790M/C797S TK, respectively. Os30 can suppress EGFR phosphorylation, arrest at G1 phase and induce the apoptosis of KC-0116 (BaF3-EGFRDel19/T790M/C797S) cells. Os30 shows potent antitumor efficacy on non-small cell lung cancer (NSCLC) with EGFmRC797S mutation .

HY-129550

BI-4020	EGFR	Cancer
BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC₅₀=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC₅₀=1 nM). BI-4020 also shows activity against EGFR wt (IC₅₀=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties .

HY-143445

EGFR-IN-48	EGFR	Cancer
EGFR-IN-48 is a potent and orally active EGFR inhibitor with IC₅₀s of 0.193 nM, 0.251 nM, 10.4 nM for EGFR ^d19/TM/CS, EGFR ^LR/TM/CS, EGFR ^WT, respectively. EGFR-IN-48 inhibits the proliferation of BaF3 ^{EGFR del19/T790M/C797S} and PC-9 ^{EGFR del19/T790M/C797S} cells with IC₅₀s of 1.526, 66.7 nM, respectively .

HY-146807

Type II TRK inhibitor 1	Trk Receptor	Cancer
Type II TRK inhibitor 1 is a potent TRK inhibitor, which inhibits various TRK fusion protein variants and wild type. Type II TRK inhibitor 1 exhibits antiproliferative activity against Ba/F3 cells harboring CD74-TRKA ^G667C and ETV6-TRKC ^G696C fusion proteins with IC₅₀s of 6 nM and 1.7 nM, respectively . Type II TRK inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163366

TRK-IN-28	Trk Receptor	Cancer
TRK-IN-28 (compound 30f) is a TRK inhibitor with the IC₅₀ values of 0.55 nM, 25.1 nM and 5.4 nM against TRK ^WT, TRK ^G595R and TRK ^G667C, respectively. TRK-IN-2 shows antiproliferative activity with IC₅₀ values of 9.5, 3.7, 205.0 and 48.3 nM against Ba/F3-ETV6-TRKA ^WT, Ba/F3-ETV6-TRKB ^WT, Ba/F3-LMNA-TRK ^G595R and Ba/F3-LMNA-TRKA ^G667C, respectively .

HY-149965

TRK-IN-23	Trk Receptor Apoptosis	Cancer
TRK-IN-23 (compound 24b) is a potent and orally active TRK inhibitor with IC₅₀ values of 0.5 nM, 9 nM, 14 nM, 4.4 nM, and 4.8 nM against TRKA, TRKC, TRKA ^G595R, TRKA ^F589L, and TRKA ^G667C, respectively. TRK-IN-23 indues apoptosis of Ba/F3-TRKAG595Rand Ba/F3-TRKAG667C cells .

HY-163004

Type II TRK inhibitor 2	Trk Receptor	Cancer
Type II TRK inhibitor 2 (compound 40l) is a selective type II TRK inhibitor with plasma stability and moderate hepatic microsomal stability. Type II TRK inhibitor 2 significantly inhibits Km-12, Ba/F3-TRKA ^G595R and Ba/F3-TRKA ^G667C cell proliferation (IC₅₀: 4.1 nM, 41.5 nM, 1.4 nM). Type II TRK inhibitor 2 can be used to study NTRK fusion cancers .

HY-144069

Pan-Trk-IN-3	Trk Receptor Apoptosis	Cancer
Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-Trk and their drug-resistant mutants with IC₅₀ values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against TrkA, TrkB, TrkC, TrkA ^G595R, TrkA ^G667C, TrkA ^G667S, TrkA ^F589L and TrkC ^G623R, respectively. Pan-Trk-IN-3 displays excellent antitumor activity and induces apoptosis .

HY-147621

FGFR-IN-6	FGFR	Cancer
FGFR-IN-6 (Compound 5) is a FGFR inhibitor . FGFR-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-11007

GNF-2 2 Publications Verification	Bcr-Abl SARS-CoV	Cancer
GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC₅₀ of 138 nM .

HY-136526

BCR-ABL-IN-3

Bcr-Abl Cancer

BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC₅₀ of ≤100 nM for Ba/F₃Bcr-Abl ^T3151. BCR-ABL-IN-3 has anti-cancer activity .

HY-15456

NVP-BVU972	c-Met/HGFR	Cancer
NVP-BVU972 is an selective and potent Met inhibitor, with an IC₅₀ of 14 nM. NVP-BVU972 also exhibits good anti-proliferative activity against Met with drug-resistant mutations and inhibits phosphorylation. NVP-BVU972 can be used in study of cancer .

HY-144451

TRK-IN-12	Trk Receptor	Cancer
TRK-IN-12 (Compound 9e) is a potent inhibitor of TRK (TRK ^G595R IC₅₀ = 13.1 nM). TRK-IN-12 is a macrocyclic derivative compound. TRK-IN-12 shows significant antiproliferative activity in the Ba/F3-LMNA-NTRK1 cell line (IC₅₀ = 0.080 μM). TRK-IN-12 has shown a better inhibitory effect (IC₅₀ = 0.646 μM) than control agent LOXO-101 in Ba/F3-LMNA-NTRK1-G595R cell line .

HY-146697

IHMT-TRK-284	Trk Receptor c-Fms PDGFR Bcr-Abl c-Kit Apoptosis	Cancer
IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC₅₀ values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BAF3

Inhibitors & Agonists